Menu

Placental Health Influences Baby’s Future Schizophrenia Risk, Study Suggests

Complications during pregnancy may act via the placenta to magnify the effects of genetic risk factors.

May 29, 2018
Shawna Williams

ISTOCK, ILBUSCAComplications during pregnancy can magnify the effect of genetic risk factors for schizophrenia by altering gene expression in the placenta, a new study suggests. The paper appeared yesterday (May 28) in Nature Medicine.

“To me the key thing in this paper is the recognition that environmental factors in early development, prenatal factors, are likely to be very important in schizophrenia and just as important as genes,” Allan Brown of Columbia University Medical Center who was not involved in the study tells Scientific American.

An international team of researchers analyzed data from nearly 3,000 participants, including people with schizophrenia and healthy controls. The researchers found that, among people with known genetic risk factors, those who were products of a pregnancy complicated by conditions such as preeclampsia or diabetes were at least five times more likely to have the disease than were people born of uncomplicated pregnancies.

The researchers also analyzed gene expression in placental tissue from complicated and uncomplicated pregnancies. That assay revealed that genes associated with schizophrenia risk tended to be “turned on” in the placentas from complicated pregnancies, and that higher expression of those genes was associated with inflammation and other signs of stress in the tissue.

“We need to create a new risk score for schizophrenia, incorporating not only genes but also placental health,” study coauthor Daniel Weinberger of the Lieber Institute for Brain Research and the Johns Hopkins University School of Medicine tells STAT. “The odds of becoming schizophrenic based on your polygenic risk score is more than 10 times greater with these early-life complications than without them.”

June 2019

Living with Bacteria

Can pathogens be converted to commensals?

Marketplace

Sponsored Product Updates

Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics
Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics
Ready-to-use immunoassay kit increases analytical output and productivity in bioprocess workflows. Kit developed as part of licensing and supply agreement with Cygnus Technologies
IDT launches ultra-high performance CRISPR Cas12a enzyme
IDT launches ultra-high performance CRISPR Cas12a enzyme
IDT’s new CRISPR Cas12a (Cpf1) Ultra enzyme can target new sites within the genome and with greater efficiency
Implen Launches New NanoPhotometer N120: The High Throughput Champion!
Implen Launches New NanoPhotometer N120: The High Throughput Champion!
Implen GmbH is excited to announce the release of the NanoPhotometer® N120, an absorbance based UV/VIS Multi Channel Spectrophotometer.
StemExpress Announces Release of New Frozen Leukopak® to Advance Research
StemExpress Announces Release of New Frozen Leukopak® to Advance Research
To continue to provide new products and services to further advance medical research around the world, today, StemExpress announced the release of their Frozen Leukopak®.